| Literature DB >> 35744917 |
Fanqiang Zeng1, Yongli Xu2, Yilian Li1, Zhigang Yan2, Li Li3.
Abstract
Maoji Jiu (MJ) is a kind of medicinal wine that has been widely used by Chinese people for many years to nourish and promote blood circulation. The purpose of this study was to investigate the hematopoietic effect of MJ on the metabolism of blood deficient rats and to explore the underlying hematopoietic regulation mechanisms. Blood deficiency model rats were induced by subcutaneous injection of N-acetylphenylhydrazine (APH) and intraperitoneal injection of cyclophosphamide (CTX). The plasma metabolic fingerprints of blood deficiency model rats with and without MJ treatment were obtained by using metabonomics based on ultra-high-performance liquid chromatography coupled to quadrupole time-of-flight mass spectrometry (UHPLC-QTOF/MS). Orthogonal partial least squares-discriminant analysis (OPLS-DA) was used to evaluate the hematopoietic effect of MJ and identify potential biomarkers in the plasma of blood deficiency model rats. The levels of white blood cells (WBC), red blood cells (RBC) and hemoglobin (HGB) and the activity of antioxidant capacity showed a recovery trend to the control group after MJ treatment, while the dose of 10 mL/kg showed the best effect. In this study, thirteen potential biomarkers were identified, which were mainly related to seven metabolic pathways, including linoleic acid metabolism, d-glutamine and d-glutamate metabolism, alanine, aspartate and glutamate metabolism, tryptophan metabolism, pyrimidine metabolism, porphyrin and chlorophyll metabolism and arginine biosynthesis. Metabolomics was applied frequently to reflect the physiological and metabolic state of organisms comprehensively, indicating that the rapid plasma metabonomics may be a potentially powerful tool to reveal the efficacy and enriching blood mechanism of MJ.Entities:
Keywords: Maoji Jiu; biomarkers; blood deficiency; hematopoietic effect; metabolomics
Mesh:
Substances:
Year: 2022 PMID: 35744917 PMCID: PMC9227738 DOI: 10.3390/molecules27123791
Source DB: PubMed Journal: Molecules ISSN: 1420-3049 Impact factor: 4.927
Figure 1(A) Peripheral blood routine analysis. (B) Antioxidant activity analysis. (C,D) Representative base peak intensity chromatogram of plasma samples in MJ-H group derived from UHPLC–QTOF/MS, peak 1, Uracil; 2, Cytidine; 3, Picolinic acid; 4, l-Glutamate; 5, Glutathione disulfide; 6, Linoleic acid; 7, Formylanthranilic acid; 8, Bilirubin; 9, Uridine; 10, Protoporphyrin; 11, 5-Hydroxyindoleacetate; 12, Orotate; 13, l-Tryptophan. (* p < 0.01, compared with control group; compared with model group, # p < 0.05, ## p < 0.01.)
Figure 2Multivariate data analysis between control and model groups in positive mode. (A) PCA score plot. (B) OPLS–DA score plot. (C) Permutation test of OPLS–DA model. (D,E) OPLS–DA score plot between the treatment groups and control group. (F) Volcano plot.
The relative distances between the treatment groups and the control group from the OPLS–DA score plots of the plasma samples.
| ESI | Control Group | Model Group | MJ-H | MJ-M | MJ-L | |
|---|---|---|---|---|---|---|
| + | 23.32 | −4.23 | 32.62 ± 5.03 | 27.40 ± 2.77 * | 32.05 ± 2.53 | 33.45 ± 2.85 |
| − | 23.39 | −6.81 | 34.80 ± 2.69 | 30.08 ± 3.46 * | 32.63 ± 0.98 | 28.93 ± 4.07 * |
* p < 0.05, compared with model group.
Metabolites selected as potential biomarkers characterized in plasma profile and their change trends (n = 6 in each group).
| No. | ESI | tR | VIP |
| HMDB | Metabolites | Trend in Model Group a | Trend in MJ-H Group b | Trend in MJ-M Group b | Trend in MJ-L Group b | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | + | 2.53 | 113.0342 | 2.22 | 0.0025 | 00300 | Uracil | ↑ ** | ↓ ** | ↓ ** | ↓ * |
| 2 | + | 3.71 | 266.0743 | 2.22 | 0.0011 | 00089 | Cytidine | ↑ ** | ↓ * | ↓ * | ↓ |
| 3 | + | 5.04 | 124.0387 | 1.96 | 0.0157 | 02243 | Picolinic acid | ↓ ** | ↑ * | ↑ | ↑ |
| 4 | + | 6.21 | 148.0602 | 1.40 | 0.0489 | 00148 | L-Glutamate | ↑ * | ↓ * | ↓ | ↓ |
| 5 | + | 7.85 | 613.5462 | 2.04 | 0.0003 | 03337 | Glutathione disulfide | ↓ ** | ↑ * | ↑ | ↑ |
| 6 | − | 0.75 | 279.2280 | 1.79 | 0.0066 | 00673 | Linoleic acid | ↑ ** | ↓ * | ↓ * | ↓ |
| 7 | − | 1.00 | 164.0327 | 1.49 | 0.0093 | 04089 | Formylanthranilic acid | ↓ ** | ↑ ** | ↑ * | ↑ |
| 8 | − | 1.27 | 583.2440 | 1.20 | 0.0307 | 00054 | Bilirubin | ↑ ** | ↓ * | ↓ * | ↓ |
| 9 | − | 2.57 | 265.0383 | 1.56 | 0.0197 | 00296 | Uridine | ↑ ** | ↓ * | ↓ | ↓ |
| 10 | − | 2.84 | 561.2397 | 1.93 | 0.0013 | 00241 | Protoporphyrin | ↑ ** | ↓ ** | ↓ * | ↓ * |
| 11 | − | 3.13 | 190.0476 | 1.67 | 0.0022 | 00763 | 5-Hydroxyindoleacetate | ↓ ** | ↑ ** | ↑ ** | ↑ * |
| 12 | − | 3.62 | 155.0065 | 1.34 | 0.0368 | 00226 | Orotate | ↑ ** | ↓ ** | ↓ * | ↓ |
| 13 | − | 3.98 | 203.0791 | 1.66 | 0.0036 | 00929 | L-Tryptophan | ↓ ** | ↑ * | ↑ | ↑ |
a Change trend compared with control group. b Change trend compared with model group. The levels of potential biomarkers were labeled with (↓) down-regulated and (↑) up-regulated (* p < 0.05; ** p < 0.01).
Figure 3Metabolic pathways of plasma samples of blood deficiency model rats.
Figure 4Correlation networks of main potential biomarkers related to blood deficiency and the effects of treatment for blood deficiency. The contents of potential biomarkers in model group compared to control group were marked with (↑) up-regulated and (↓) down-regulated.